Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by chrispion Jan 30, 2022 12:17pm
154 Views
Post# 34376095

RE:RE:RE:RE:You know you're a bagholder when....

RE:RE:RE:RE:You know you're a bagholder when....Chrispi the muppet has all the inside information that can't be shared, except that something big is just about to always happen.   Been spouting the same pro-management claptrap for 2+ years and zero has been accomplished to get anything to clinical.  ALWAYS 100% wrong, but claims every buried, out of patience and nearly dead shareholder is an idiot.

As JD states, since we don't yet have any programs in the clinic (human dosing) we are really left for (non financial and general company) news generation with:
  • any internal studies that we do,
  • external studies (not done by us),
  • licensing deals
  • partnership deals (which I'll also include as MTAs)
We are a small biotech company so it goes without saying that even if we did have programs in the clinic the nature of the business is that there are big gaps in news flow as we wait while dosing is done, many months, even a year or two.

Licensing and partnership deals take time in the biotech world (much more so than other industries) and we were always between a rock and a hard place with poor leadership (when Mark Day was CEO) or lack of funds or COVID delays. What I was expecting the company to accomplish by now has just been extended a bit ... still game on, just a few more extra innings.
 
I think you’ll see this year what exactly the company has been busy working on for the past two years!



<< Previous
Bullboard Posts
Next >>